| 2025/09/01 | 16:46:53 | Medeon, on behalf of its subsidiary PMC, announces the resolution of BOD on the issuance of Series F Preferred Stocks | |
| SEQ_NO |
2 |
Date of announcement |
2025/09/01 |
Time of announcement |
16:46:53 |
| Subject |
Medeon, on behalf of its subsidiary PMC, announces the resolution of BOD on the issuance of Series F Preferred Stocks |
| Date of events |
2025/09/01
|
To which item it meets |
paragraph 11 |
| Statement |
1.Date of the board of directors resolution:2025/09/01
2.Source of capital increase funds:
Issuance of New Shares of Series F Preferred Stock for Cash Capital
Increase
3.Whether to adopt shelf registration
(Yes, please state issuance period/No):No
4.Total monetary value of the issuance and number of shares issued (shares
issued not including those distributed to employees if consisting in
capital increase from earnings or capital surplus):
Total monetary value of the issuance?GNT$35,000,000
Number of shares issued?GSeries F Preferred Stock 3,500,000 shares
5.If adopting shelf registration, monetary value and number of shares
to be issued this time:NA
6.The remaining monetary value and shares after this issuance when
adopting shelf registration:NA
7.Par value per share:NT$10
8.Issue price:NT$84
9.Number of shares subscribed for by or allocated to employees:
10% of the total issued shares, amounting to 350,000 shares, are
reserved for subscription by the PMC’s employees.
10.Number of shares publicly sold:NA
11.Ratio of shares subscribed by or allotted as stock
dividends to existing shareholders:
The remaining number of shares to be issued will be subscribed in
proportion to the shareholders and their shareholdings as recorded in
the shareholders’ register on the basis of the subscription date.
12.Handling method for fractional shares and shares
unsubscripted for by the deadline:
Shares renounced by original shareholders and employees, or fractional
shares that are less than one share, are authorized to be subscribed
by the Chairman of the Board of Directors through a specific person at
the issue price.
13.Rights and obligations of these newly issued shares:
1. Issuance of Series F Preferred Stock
The Series F Preferred Stock will be issued at NTD 84 per share with
an estimated number of 3,500,000 shares to be issued in one or
several times.
2. Dividends of the Preferred Stock
The annual dividend rate of Series F Preferred Stock is 8% per annum,
and based on the issue price per share and actual number of issue
days.
After the annual general meeting of shareholders has recognized the
financial statements of the previous year and resolved to distribute
the earnings, the dividends of preferred stocks shall be distributed
lump sum in cash at one time in advance, and the ex-dividend date of
the dividend of preferred stock shall be determined by the resolution
of the authorized Board of Directors.
If there is no surplus or insufficient surplus to pay the dividend of
preferred stock or if the Company resolves not to distribute the
surplus, the undistributed or under-distributed dividend shall not
be cumulative.
Preferred stock is not eligible to participate in the distribution
of common stock in respect of earnings and capital surplus, except
for the receipt of the dividends mentioned above.
3. Right of voting and candidate eligibility
The stockholders of preferred stocks shall have the right to vote
and to be a candidate of director at the common stockholders’
meeting, the number of voting rights of a shareholder are based on
the number of shares of common stock available at that time based on
the conversion price.
A resolution of the shareholders’ meeting according to Articles 185,
277 and 316 of the Company Act shall be approved by a majority of the
voting rights of the preferred shareholders at a meeting where
shareholders of preferred stocks representing more than two-thirds
of the total number of outstanding preferred shares are present.
4. Pre-emptive right
When the Company issues new shares by cash capital increase, the
shareholders of preferred stocks have the same pre-emptive right to
subscribe for the new shares as the shareholders of common stocks.
5. Liquidation Preference
In the event that the Company resolves to dissolve, cease operations
or liquidate in accordance with Article 316 of the Company Act, the
liquidation preference of this paragraph shall apply.
In the event of the Company’s outstanding shares possessed by
existing shareholders less than 50% of entire Company’s outstanding
shares, the Company shall be deemed to be in liquidation and the
liquidation preference in this paragraph shall apply.
When the previous two conditions for liquidation preference are me,
the Company shall distribute the remaining assets of the Company in
the following manner:
(1) The distribution of the remaining property of the Company by the
preferred stock shall take precedence over the common stock,
with the Series F Preferred Stock calculated at an issue price
of $84 NT per share (hereinafter referred to as the ‘Series F
Preferred Stock Liquidation Preference Amount’); if the
remaining property of the Company is insufficient to satisfy the
aggregate amount of the Series F preferred stock Liquidation
Preference Amount and the Liquidation Preference Amounts of the
other series of preferred stock (hereinafter referred to as the
‘Liquidation Preference Amounts’), then the preferred
stockholders shall distribute the remaining property of the
Company in proportion to the ratio of the number of shares of
preferred stock held by them to the number of shares of all
outstanding preferred stock.
(2) If there is any balance remaining after the distribution, it
shall be distributed in accordance with the ratio among the
number of common shares held by shareholders of preferred stocks
converted from their preferred stocks at the conversion price
and the number of shares held by the shareholders of common
stocks.
6. Conversion of Preferred Stock
The preferred stockholders may convert the preferred stock into
common stock at the issue price (i.e., at a ratio of one common
stock for every one preferred stock) starting from the next day
after the issue date. The rights and obligations of the common
shares converted from preferred shares are the same as those of
the Company’s other outstanding common shares.
Upon conversion of convertible preferred stock into common stock,
the rights and obligations are the same as those for common stock.
If the preferred stock has been converted to common stock before
the ex-dividend record date of the year of conversion, and the
converted preferred stock participates in the distribution of
earnings and capital surplus in the current year, which will not
be eligible to participate preferred stock dividend distribution
in the same year.
7. Other rights and obligations of the Preferred Stocks are the same
as those of the Common Stocks.
14.Utilization of the funds from the capital increase:
Future product development and operation requirements
15.Any other matters that need to be specified:None |
|
| 2025/09/01 | 16:14:50 | Medeon’s Board of Directors approved the cash capital increase through the issuance of common shares. | |
| SEQ_NO |
1 |
Date of announcement |
2025/09/01 |
Time of announcement |
16:14:50 |
| Subject |
Medeon’s Board of Directors approved the cash capital increase through the issuance of common shares. |
| Date of events |
2025/09/01
|
To which item it meets |
paragraph 11 |
| Statement |
1.Date of the board of directors resolution:2025/09/01
2.Source of capital increase funds:
Cash capital increase through the issuance of common shares
3.Whether to adopt shelf registration
(Yes, please state issuance period/No):No
4.Total monetary value of the issuance and number of shares issued (shares
issued not including those distributed to employees if consisting in
capital increase from earnings or capital surplus):
Issuance of 4,700,000 common shares
5.If adopting shelf registration, monetary value and number of shares
to be issued this time:N/A
6.The remaining monetary value and shares after this issuance when
adopting shelf registration:N/A
7.Par value per share:NTD 10
8.Issue price:
The actual issuance price shall be determined by the Chairman, upon
approval of the competent authority, in consultation with the lead
underwriter and in accordance with Article 6 of the ‘Self-Regulation
Rules for Securities Underwriters Assisting Companies in Offering and
Issuing Securities’ of the ROC Securities Association and other
applicable laws and regulations.
9.Number of shares subscribed for by or allocated to employees:
In accordance with Article 267 of the Company Act, 15% of the total
shares to be issued, amounting to 705,000 shares, shall be reserved
for subscription by the Company’s employees.
10.Number of shares publicly sold:
In accordance with Article 28-1 of the Securities and Exchange Act,
10% of the total issued shares shall be allocated for public offering.
11.Ratio of shares subscribed by or allotted as stock
dividends to existing shareholders:
The remaining 75% of the shares shall be subscribed by the shareholders
listed on the shareholders’ register as of the record date in
proportion to their respective shareholdings.
12.Handling method for fractional shares and shares
unsubscripted for by the deadline:
Fractional shares resulting from subscriptions of less than one full
share may be combined into whole shares by shareholders directly with
the Company’s stock transfer agent within five days from the
suspension of share transfer. Shares that are forfeited by existing
shareholders or employees who waive their subscription rights, or any
remaining fractional shares, are hereby authorized to be subscribed by
the Chairman, on behalf of the Company, by designated persons at the
issuance price.
13.Rights and obligations of these newly issued shares:
The new shares issued in this cash capital increase will be issued in
dematerialized form and shall carry the same rights and obligations as
the existing shares.
14.Utilization of the funds from the capital increase:Investee subsidiary
15.Any other matters that need to be specified:
(1) Upon the effectiveness of the filing with the competent authority
for this cash capital increase, the Company intends to request the
Board of Directors to authorize the Chairman to determine the
record date for subscription, the payment period, the capital
increase effective date, and other related matters.
(2) The key details of this cash capital increase plan include the
source of funds, planned projects, expected schedule, and
anticipated benefits. Should there be any amendments required by
the competent authority, any matters not fully addressed, or
changes necessitated by objective circumstances, the Company
intends to request the Board of Directors to authorize the Chairman
to handle such matters with full discretion. If the actual issuance
price per share is adjusted due to market fluctuations and results
in a shortfall in the funds to be raised, the shortfall shall be
covered by the Company’s own funds. Conversely, if the funds
raised exceed the target, the surplus shall be used to strengthen
the Company’s operating capital. |
|
| 2025/08/07 | 17:46:32 | Announcement for the issuance of new shares for cash capital increase on behalf of Medeon’s major subsidiary, AMI | |
| SEQ_NO |
4 |
Date of announcement |
2025/08/07 |
Time of announcement |
17:46:32 |
| Subject |
Announcement for the issuance of new shares for cash capital increase on behalf of Medeon’s major subsidiary, AMI |
| Date of events |
2025/08/07
|
To which item it meets |
paragraph 11 |
| Statement |
1.Date of the board of directors resolution:2025/08/07
2.Source of capital increase funds:
Issuance of preferred stocks for cash capital increase
3.Whether to adopt shelf registration
(Yes, please state issuance period/No):No
4.Total monetary value of the issuance and number of shares issued (shares
issued not including those distributed to employees if consisting in
capital increase from earnings or capital surplus):
Total monetary value of the issuance?GUS$2,000,130
Number of shares issued?G689,700 shares
5.If adopting shelf registration, monetary value and number of shares
to be issued this time:N/A
6.The remaining monetary value and shares after this issuance when
adopting shelf registration:N/A
7.Par value per share:US$0.0001
8.Issue price:US$2.9
9.Number of shares subscribed for by or allocated to employees:N/A
10.Number of shares publicly sold:N/A
11.Ratio of shares subscribed by or allotted as stock
dividends to existing shareholders:100%
12.Handling method for fractional shares and shares
unsubscripted for by the deadline:N/A
13.Rights and obligations of these newly issued shares:
The rights and obligations of the newly issued shares from this cash capital
increase are the same as those of existing preferred shares.
14.Utilization of the funds from the capital increase:
Program development requirements
15.Any other matters that need to be specified:None |
|
| 2025/08/07 | 17:41:36 | Announcement for the issuance of new shares for cash capital increase on behalf of Medeon’s major subsidiary, Medeon International, Inc. | |
| SEQ_NO |
3 |
Date of announcement |
2025/08/07 |
Time of announcement |
17:41:36 |
| Subject |
Announcement for the issuance of new shares for cash capital increase on behalf of Medeon’s major subsidiary, Medeon International, Inc. |
| Date of events |
2025/08/07
|
To which item it meets |
paragraph 11 |
| Statement |
1.Date of the board of directors resolution:2025/08/07
2.Source of capital increase funds:
Issuance of common shares for cash capital increase
3.Whether to adopt shelf registration
(Yes, please state issuance period/No):No
4.Total monetary value of the issuance and number of shares issued (shares
issued not including those distributed to employees if consisting in
capital increase from earnings or capital surplus):
Total monetary value of the issuance?GUS$2,000,130
Number of shares issued?G2,000,130 shares
5.If adopting shelf registration, monetary value and number of shares
to be issued this time:N/A
6.The remaining monetary value and shares after this issuance when
adopting shelf registration:N/A
7.Par value per share:US$1
8.Issue price:US$1
9.Number of shares subscribed for by or allocated to employees:N/A
10.Number of shares publicly sold:N/A
11.Ratio of shares subscribed by or allotted as stock
dividends to existing shareholders:100%
12.Handling method for fractional shares and shares
unsubscripted for by the deadline:N/A
13.Rights and obligations of these newly issued shares:
The rights and obligations of the newly issued shares from this
cash capital increase are the same as those of existing shares.
14.Utilization of the funds from the capital increase:
To invest in subsidiary
15.Any other matters that need to be specified:None |
|
| 2025/08/07 | 17:36:25 | Medeon’s Board of Directors approved the appointment of its Accounting Officer. | |
| SEQ_NO |
2 |
Date of announcement |
2025/08/07 |
Time of announcement |
17:36:25 |
| Subject |
Medeon’s Board of Directors approved the appointment of its Accounting Officer. |
| Date of events |
2025/08/07
|
To which item it meets |
paragraph 8 |
| Statement |
1.Type of personnel changed (please enter:
spokesperson, acting spokesperson, important
personnel (CEO, COO, CMO, CSO, etc.), financial
officer, accounting officer, corporate governance
officer, chief information security officer,research
and development officer, internal audit officer, or
designated and non-designated representatives):Accounting Officer
2.Date of occurrence of the change:2025/08/07
3.Name, title, and resume of the previous position holder:
Javin Wang (Acting) / Assistant Manager, Medeon Biodesign, Inc.
4.Name, title, and resume of the new position holder:
Javin Wang / Manager, Medeon Biodesign, Inc.
5.Type of change (please enter: ‘resignation’,
‘position adjustment’, ‘dismissal’, ‘retirement’,
‘death’ or ‘new replacement’):new replacemen
6.Reason for the change:new replacemen
7.Effective date:2025/08/07
8.Any other matters that need to be specified:
On June 30, 2025, Medeon announced a change in its Accounting Officer.
As of August 7, 2025, the appointment of Ms. Javin Wang as the
Accounting Officer of the Company has been approved by the Audit Committee
and the Board of Directors. |
|
| 2025/08/07 | 17:31:11 | Medeon Board of Directors approved the 2025Q2 consolidated financial reports | |
| SEQ_NO |
1 |
Date of announcement |
2025/08/07 |
Time of announcement |
17:31:11 |
| Subject |
Medeon Board of Directors approved the 2025Q2 consolidated financial reports |
| Date of events |
2025/08/07
|
To which item it meets |
paragraph 31 |
| Statement |
1.Date of the board of directors submitted or approved:2025/08/07
2.Date of the audit committee approved:2025/08/07
3.Start and end dates of financial reports or unaudited financial
information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):
2025/01/01~2025/06/30
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):212,260
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):32,015
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):(374,614)
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):(379,094)
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):(378,850)
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):(356,153)
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):(3.86)
11.Total assets end of the period (thousand NTD):1,417,122
12.Total liabilities end of the period
(thousand NTD):284,528
13.Equity attributable to owners of parent end of the
period (thousand NTD):1,103,853
14.Any other matters that need to be specified:None |
|
| 2025/07/30 | 17:09:17 | Announcement of the Board of Directors Meeting Date for Approval of the Second-Quarter 2025 Financial Report | |
| SEQ_NO |
1 |
Date of announcement |
2025/07/30 |
Time of announcement |
17:09:17 |
| Subject |
Announcement of the Board of Directors Meeting Date for Approval of the Second-Quarter 2025 Financial Report |
| Date of events |
2025/07/30
|
To which item it meets |
paragraph 31 |
| Statement |
1.Date of a notice of the board of directors meeting is issued:2025/07/30
2.Expected date of the board of directors meeting is convened:2025/08/07
3.Expected year and quarter of the financial reports
or the annual self-assessed financial information
submitted to the board of directors or approved by
the board of directors: Second-Quarter 2025
4.Any other matters that need to be specified:None |
|
| 2025/07/15 | 13:33:10 | The Company has been required by TPEx to announce the financial data according to the regulations. | |
| SEQ_NO |
1 |
Date of announcement |
2025/07/15 |
Time of announcement |
13:33:10 |
| Subject |
The Company has been required by TPEx to announce the financial data according to the regulations. |
| Date of events |
2025/07/15
|
To which item it meets |
paragraph 53 |
| Statement |
1.Date of occurrence of the event: 2025/07/15
2.Cause of occurrence:Announced as required by the TPEx
3.Financial and business information:
Unit: (NT$million)
(1) Monthly
June 2025 June 2024 YoY Change %
—————————————————————————
Sales revenue 39.246 22.097 77.61%
Loss before income tax (55.569) (79.617) 30.20%
Net Loss attributable to
Owners of the parent (52.460) (73.835) 28.95%
EPS (NT$) (0.57) (0.80) 28.75%(Losses reduced)
===========================================================================
(2)Quarterly
Q1 2025 Q1 2024 YoY Change %
—————————————————————————
Sales revenue 101.878 47.141 116.11%
Loss before income tax (190.856) (214.799) 11.15%
Net Loss attributable to
Owners of the parent (177.993) (199.827) 10.93%
EPS (NT$) (1.93) (2.17) 11.06%(Losses reduced)
===========================================================================
(3)Cumulative for the last four seasons
Latest 4 quarters accumulation
(Q2 2024 to Q1 2025)
—————————————————————————
Revenue 347.545
Loss before income tax (834.700)
Net Loss attributable to
Owners of the parent (783.678)
EPS (NT$) (8.50)
===========================================================================
4.Any material information that needs to be specified
according to Article 4 of Taipei Exchange Procedures
for Verification and Disclosure of Material Information
of Companies with TPEx Listed Securities:
Medeon has not released any material information
in the past six business days.
5.Any material information in a press conference listed
under Article 11 of Taipei Exchange Procedures for
Verification and Disclosure of Material Information of
Companies with TPEx Listed Securities:
Medeon has not held any press conferences to explain material information
in the past six business days.
6.Any other matters that need to be specified:
(1)The aforementioned financial information for June 2025 and its YOY
comparison consists in the consolidated reviewed amounts prepared by
the Company adopting the IFRS, and has not been audited (reviewed)
by CPA; it is only for reference by investors.
(2)The information for the latest quarter (Q1 2025) refers to single
quarter amounts, not cumulative amounts from the latest financial
reports, and are consolidated amounts prepared under the IFRS,
which have been audited (reviewed) by CPA; it is only for reference
by investors.
(3)The information accumulated over the last 4 quarters consists in the
consolidated amounts from Q2 2024 to Q1 2025 prepared by the Company
adopting the IFRS, and has been audited (reviewed) by CPA; it is only
for reference by investors. |
|
| 2025/07/01 | 03:20:12 | Receiving the Complaint Requesting to Attend Mediation | |
| SEQ_NO |
1 |
Date of announcement |
2025/07/01 |
Time of announcement |
03:20:12 |
| Subject |
Receiving the Complaint Requesting to Attend Mediation |
| Date of events |
2025/06/30
|
To which item it meets |
paragraph 2 |
| Statement |
1.Parties to the legal matter:
Securities and Futures Investors Protection Center (‘SFIPC’),
Jung Chin Lin, Medeon Biodesign, Inc., Wechen Co., Ltd.,
Pei-Chen Tsai, and Center Laboratories, Inc.
2.Name of the court or punishing agency of the legal matter:
Intellectual Property and Commercial Court
3.Reference/Case number of relevant documents of the legal matter:
2025 Commercial Case Mediation No. 18.
4.Date of occurrence of the event:2025/06/30
5.Details of occurrence (including the matter under dispute):
SFIPC claims for discharging Jung Chin Lin’s directorship in the Company.
6.Handling procedure:Mediation Notice Received.
7.Impact on the Company’s finance and business and projected amount:
No impact on the finance and operation of the Company.
8.Countermeasures and improvement status:
Engaging legal counsel for advice and subsequent solutions.
9.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 2
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):None |
|
| 2025/06/30 | 16:46:05 | Announcement of a change in the accounting officer | |
| SEQ_NO |
1 |
Date of announcement |
2025/06/30 |
Time of announcement |
16:46:05 |
| Subject |
Announcement of a change in the accounting officer |
| Date of events |
2025/06/30
|
To which item it meets |
paragraph 8 |
| Statement |
1.Type of personnel changed (please enter:
spokesperson, acting spokesperson, important
personnel (CEO, COO, CMO, CSO, etc.), financial
officer, accounting officer, corporate governance
officer, chief information security officer,research
and development officer, internal audit officer, or
designated and non-designated representatives):Accounting Officer
2.Date of occurrence of the change:2025/06/30
3.Name, title, and resume of the previous position holder:
Tori Lin / Senior Manager, Medeon Biodesign, Inc.
4.Name, title, and resume of the new position holder:
Javin Wang (Acting) / Assistant Manager, Medeon Biodesign, Inc.
5.Type of change (please enter: ‘resignation’,
‘position adjustment’, ‘dismissal’, ‘retirement’,
‘death’ or ‘new replacement’):Resignation
6.Reason for the change:Resignation
7.Effective date:2025/06/30
8.Any other matters that need to be specified:
The appointment of the new accounting officer is subject to the approval
by the forthcoming Audit Committee and Board of Directors. |
|
